Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia

This publication has 41 references indexed in Scilit:

• RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance
  Blood, 2008
• An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor Therapy
  The Journal of Molecular Diagnostics, 2008
• Monitoring treatment of chronic myeloid leukemia
  Haematologica, 2008
• Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
  Blood, 2007
• Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
  The Lancet Oncology, 2007
• Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
  Blood, 2007
• Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
  Journal of Clinical Investigation, 2007
• Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
  Blood, 2007
• Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study
  Blood, 2007
• Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements
  Leukemia, 2007